TCT 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Shows Low Five-Year Event Rates in BIOFLOW-II RCT and BIOFLOW-III Registry
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
Data presented during the TCT congress on BIOTRONIK’s Magmaris1 RMS provide further evidence on its continued safety and…
Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is ga…
BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical pe…
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce…
Der resorbierbare Magnesium-Scaffold Magmaris zeigt ein reduziertes Risiko für die Bildung von Thromben im Vergleich zum…
BIOTRONIK’s Magmaris resorbable scaffold offers a reduced risk of thrombus formation compared to a polymeric scaffold*.…
Die 24-Monats-Daten der BIOSOLVE-II Studie belegen die Langzeitsicherheit, -wirksamkeit und -stabilität des Magnesium-Sc…
Twenty-four month data from the BIOSOLVE-II study reveal the long-term safety, efficacy and stability of BIOTRONIK’s Mag…
BIOTRONIK’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the…